Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Holdings Decreased by Towerview LLC

Towerview LLC decreased its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 34.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,500 shares of the company’s stock after selling 40,000 shares during the quarter. Corvus Pharmaceuticals accounts for approximately 0.3% of Towerview LLC’s holdings, making the stock its 19th biggest position. Towerview LLC owned approximately 0.12% of Corvus Pharmaceuticals worth $415,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Nwam LLC acquired a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $53,000. China Universal Asset Management Co. Ltd. acquired a new position in Corvus Pharmaceuticals in the 4th quarter worth about $73,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $74,000. Virtu Financial LLC acquired a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $83,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $89,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Down 5.1 %

Shares of NASDAQ:CRVS opened at $3.94 on Friday. The business has a 50 day moving average price of $5.08 and a 200 day moving average price of $6.05. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.30 and a twelve month high of $10.00. The company has a market cap of $253.17 million, a price-to-earnings ratio of -4.24 and a beta of 1.07.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CRVS. Oppenheimer upped their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.38.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.